Abstract
Hepatitis B is a necroinflammatory liver disease manifested with subacute to acute symptoms, liver cirrhosis, and mortality. Parenteral alum-adsorbed hepatitis B surface antigenic (HBsAg) vaccination, although available, poses serious concerns regarding inability to induce both cell-mediated and mucosal immune response. In this context, oral delivery may be a prospective solution to the issues associated with conventional vaccination. However, the strategy is detrimental to the antigenic substances, suffers various physical/chemical barriers, and impedes poor transcytosis via mucosal route. Therefore, surface-engineered novel carrier-based approaches are reportedly promising for effective HBsAg oral vaccine delivery. This review focuses on the efforts for developing oral mucosal vaccine against hepatitis B, with considerable attention on novel drug delivery systems for spatial distribution of antigenic substance to the immune effector cells and organs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
